ALK and non-small cell lung carcinoma: More recently, a comprehensive cfDNA analysis with the Guardant360 on 282 prospectively enrolled patients with previously untreated metastatic NSCLC showed that the genotyping of cfDNA for eight recommended markers, including EGFR, BRAF, and ERBB2 mutations, ALK, ROS1, and RET fusions, and MET aberrations (amplification and exon 14 skipping variants) was a clinically relevant alternative to tissue genotyping.